Literature DB >> 25532607

Correlation between chronotropic incompetence and metabolic equivalents in patients with type 2 diabetes mellitus and concomitant metabolic syndrome.

M Gao1, W Chen, Z K Gong, L Han, L Zhang.   

Abstract

AIM: The aim of the study was to examine the relationship between chronotropic incompetence and motor ability in patient with type 2 diabetes mellitus and concomitant metabolic syndrome (MS) in order to facilitate exercise prescriptions for these patients.
METHODS: A total of 120 patients with type 2 diabetes mellitus were randomly enrolled and divided into study groups with (N.=64) or without MS (N.=56). All patients completed the electrocardiographic exercise testing, after which ratio of heart rate (rHR) and heart rate reserve (HRR) were calculating to assess chronotropic incompetence. In addition, maximum metabolic equivalents (maxMETs) were calculated to assess the motor ability.
RESULTS: The MS group had significantly higher indicators of chronotropic incompetence (rHR and HRR) as well as maxMETs than patients without MS (all P<0.05). Further, maxMETs significantly correlated with rHR (r=0.81, P=0.003) and HRR (r=0.78, P<0.001).
CONCLUSION: Patients with type 2 diabetes mellitus and concomitant MS have higher chronotropic incompetence and maxMETs compared with those without MS. METs or perceived level of exertion can be used in patients in whom heart rate is not available during the exercise.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25532607

Source DB:  PubMed          Journal:  Panminerva Med        ISSN: 0031-0808            Impact factor:   5.197


  2 in total

1.  Exercise training on chronotropic response and exercise capacity in patients with type 2 diabetes mellitus.

Authors:  Li Jin; Gao Min; Chen Wei; He Min; Zhou Jie
Journal:  Exp Ther Med       Date:  2017-01-24       Impact factor: 2.447

2.  Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach.

Authors:  Lorenzo Nesti; Nicola Riccardo Pugliese; Paolo Sciuto; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2020-09-05       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.